CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by ...
Foghorn Therapeutics, Inc. ( (FHTX) ) has released its Q3 earnings. Here is a breakdown of the information Foghorn Therapeutics, Inc. presented ...
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.34 per share a year ago.
CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious ...
By way of example, Foghorn Therapeutics (NASDAQ:FHTX) has seen its share price rise 156% over the last year, delighting many shareholders. But while history lauds those rare successes, those that fail ...
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.34 per share a year ago. These ...
Foghorn Therapeutics, Inc. ( (FHTX)) has released its Q3 earnings. Here is a breakdown of the information Foghorn Therapeutics, Inc. presented to its investors. Foghorn Therapeutics, Inc., based ...
CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases ...
Nov. 04, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback